The "NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2025 Update" company profile has been added to ResearchAndMarkets.com's offering. This report is a source for data, analysis, and actionable ...
On Monday, NovoCure Ltd (NASDAQ:NVCR) and Zai Lab Limited (NASDAQ:ZLAB) revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with gemcitabine ...
NovoCure Ltd NVCR shares are trending on Thursday. Shares of the oncology company surged 29.52% to $13.60 in after-hours trading on Wednesday after the Food and Drug Administration approved Optune Pax ...
Investors in NovoCure Ltd (Symbol: NVCR) saw new options begin trading this week, for the February 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVCR ...
Analysts' ratings for NovoCure (NASDAQ:NVCR) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The following table provides a quick overview of their recent ratings, ...
Read Novocure Ltd. R (038.MU) Q3 FY2025 earnings call transcript on Yahoo Finance to keep your investing strategy up to date with all of the latest information ...
* NOVOCURE LTD - CONTINUING TO TREAT CURRENT CLINICAL TRIAL PATIENTS & ENROLL NEW PATIENTS AT EXISTING CLINICAL TRIAL SITES IN 6 ONGOING CLINICAL TRIALS * NOVOCURE LTD - COVID-19-RELATED EFFECTS ARE ...
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today it will present a real-world analysis of usage of its Tumor Treating Fields (TTFields) therapy and survival outcomes in ...
Visit a quote page and your recently viewed tickers will be displayed here. Jeryl Lynn Hilleman currently works at Omada Health, Inc., as Chairman, SI-BONE, Inc., as Independent Director from 2019, ...
Analyst Emily Bodnar of H.C. Wainwright maintained a Hold rating on NovoCure (NVCR – Research Report), with a price target of $21.00. Geoff Meacham has given his Hold rating due to a combination of ...
In a report released today, Jason Bednar from Piper Sandler assigned a Buy rating to NovoCure (NVCR – Research Report), with a price target of $42.00. The company’s shares closed last Friday at $26.17 ...
Investors in NovoCure Ltd (Symbol: NVCR) saw new options become available this week, for the January 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results